Morrison & Foerster and the Berkeley Center for Law & Technology (BCLT) have teamed up to present a recurring podcast addressing recent Federal Circuit decisions.
In this episode, Brian Matsui, a partner in Morrison & Foerster’s Appellate + Supreme Court practice and Allison Schmitt, BCLT's Life Sciences project director discuss:
- When do post-marketing tests required by the U.S. Food and Drug Administration (FDA) that lead to the claimed combination not demonstrate obviousness?
- The interplay between reasonable expectation of success and disclosed ranges in prior art.